1Bright JJ, Xin Z, Sriram S. Superantigens augment antigen-specific Thl responses by inducing IL-12 production in macrophages[ J]. J Leukoc Biol, 1999,65 ( 1 ) :5.
2Sarris AH, Daliani D, Ulmer R, et al. Interferon-inducible protein 10 as possible factor in the pathogenesis of cutaneous T-cell lymphomas [ J ]. Clinical Cancer Research, 1997,3 ( 2 ) : 169-177.
3Bunn PA Jr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrom[J]. Ann Intern Med,1994 ,121( 8 ) :592-602.
4Diamandidou E, Coghen PR, and Kurzrock R. Mycosis fungoides and Sezary syndrome[J]. Blood, 1996,88(7 ) :2385-2409.
5Gisselbrecht C, Mareninchi D, Pico JL, et al. Interleukin-2 treatment in lymphomas: A phase Ⅱ multicenter study [J].Blood, 1994,83( 8 ) :2081-2085.
6Nagatani T, Kim ST, Baba N, et al. A case of cutaneous T-cell lymphoma treated with recombinant interleukin 2 ( rIL-1 ) [ J ].Acta Derm Venerol, 1988,68 ( 6 ) : 504 -590.
7Rybojad M, Marolleau JP, Flageul B, et al. Successful interleukin-2 therapy of advanced cutaneous T-cell lymphoma( letter ) [ J ]. Br J Dermatol, 1992,127 ( 1 ) :63-64.
8Marollealu JP, Baccard N, Flageul B, et al. High-dose recombinant interleukin-2 on advanced cutaneous T-cell lymphoma [ J ]. Arch Dermatol, 1995,131 (5) :574-679.
9Baccard M, Marolleau JP, Rybojad M. Middle-term evolution of patients with advanced cutaneous T-cell lyphoma treated with high-dose recombinant interleukin-2 [ J ]. Arch Dermatol, 1997,133(5) :656.
10Foss FM, Kuzel TM. Experimental therapies in the treatment of cutaneous T-cell lymphoma [ J ]. Haematol Oncol Clin North Am,1995,(5) :1127-1137.
